Unaudited Financial Results of the company for the quarter ended 30th june, 2025 along with limited review report issued by the statutory auditor of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries has submitted its unaudited financial results for the quarter ended 30 June 2025 (Q1 FY26), reviewed by statutory auditors JAIMIN SHAH & ASSOCIATES (CA Mayank Sancheti). The auditor issued a clean limited review report with no qualifications or adverse comments, meaning nothing came to their attention suggesting material misstatement in the numbers. The figures in the filing appear garbled and could not be reliably extracted, so specific revenue, profit or margin numbers cannot be quoted. Along with the results, the Board also approved the re-appointment of Mr. Arvind Vilasrao Sapkal as a Non-executive Independent Director for a second 5-year term, subject to shareholder approval, and cleared an amendment to the 32nd AGM notice.
For shareholders, the unqualified (clean) limited review report is a positive sign, indicating the auditors found no material issues with the Q1 numbers. The re-appointment of an independent director and AGM notice changes are routine governance items with no direct effect on stock price, though the clean auditor opinion provides modest comfort on financial reporting quality.